193 related articles for article (PubMed ID: 19555215)
1. Intranasal immunization with Porphyromonas gingivalis and atherosclerosis.
Koizumi Y; Kurita-Ochiai T; Oguchi S; Yamamoto M
Immunopharmacol Immunotoxicol; 2009; 31(3):352-7. PubMed ID: 19555215
[TBL] [Abstract][Full Text] [Related]
2. Porphyromonas gingivalis mediated periodontal disease and atherosclerosis: disparate diseases with commonalities in pathogenesis through TLRs.
Gibson FC; Genco CA
Curr Pharm Des; 2007; 13(36):3665-75. PubMed ID: 18220804
[TBL] [Abstract][Full Text] [Related]
3. Construction of a sIgA-enhancing anti-Porphyromonas gingivalis FimA vaccine and nasal immunization in mice.
Guo H; Wang X; Jiang G; Yang P
Immunol Lett; 2006 Sep; 107(1):71-5. PubMed ID: 16959327
[TBL] [Abstract][Full Text] [Related]
4. Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice.
Gibson FC; Hong C; Chou HH; Yumoto H; Chen J; Lien E; Wong J; Genco CA
Circulation; 2004 Jun; 109(22):2801-6. PubMed ID: 15123526
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with recombinant adhesins from the RgpA-Kgp proteinase-adhesin complex protects against Porphyromonas gingivalis infection.
Frazer LT; O'Brien-Simpson NM; Slakeski N; Walsh KA; Veith PD; Chen CG; Barr IG; Reynolds EC
Vaccine; 2006 Oct; 24(42-43):6542-54. PubMed ID: 16839648
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and therapeutic strategies of vaccines against Porphyromonas gingivalis.
Jong RA; van der Reijden WA
Expert Rev Vaccines; 2010 Feb; 9(2):193-208. PubMed ID: 20109029
[TBL] [Abstract][Full Text] [Related]
7. Mucosal immunization with a flagellin-adjuvanted Hgp44 vaccine enhances protective immune responses in a murine Porphyromonas gingivalis infection model.
Puth S; Hong SH; Park MJ; Lee HH; Lee YS; Jeong K; Kang IC; Koh JT; Moon B; Park SC; Rhee JH; Lee SE
Hum Vaccin Immunother; 2017 Dec; 13(12):2794-2803. PubMed ID: 28604268
[TBL] [Abstract][Full Text] [Related]
8. Respiratory FimA-Specific Secretory IgA Antibodies Upregulated by DC-Targeting Nasal Double DNA Adjuvant Are Essential for Elimination of
Kataoka K; Kawabata S; Koyanagi K; Hashimoto Y; Miyake T; Fujihashi K
Front Immunol; 2021; 12():634923. PubMed ID: 33717178
[TBL] [Abstract][Full Text] [Related]
9. Gender differences in systemic inflammation and atheroma formation following Porphyromonas gingivalis infection in heterozygous apolipoprotein E-deficient mice.
Champagne C; Yoshinari N; Oetjen JA; Riché EL; Beck JD; Offenbacher S
J Periodontal Res; 2009 Oct; 44(5):569-77. PubMed ID: 18973527
[TBL] [Abstract][Full Text] [Related]
10. Immunization with malondialdehyde-modified low-density lipoprotein (LDL) reduces atherosclerosis in LDL receptor-deficient mice challenged with Porphyromonas gingivalis.
Turunen SP; Kummu O; Wang C; Harila K; Mattila R; Sahlman M; Pussinen PJ; Hörkkö S
Innate Immun; 2015 May; 21(4):370-85. PubMed ID: 25134521
[TBL] [Abstract][Full Text] [Related]
11. Pathogen-accelerated atherosclerosis occurs early after exposure and can be prevented via immunization.
Miyamoto T; Yumoto H; Takahashi Y; Davey M; Gibson FC; Genco CA
Infect Immun; 2006 Feb; 74(2):1376-80. PubMed ID: 16428788
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of mice with Porphyromonas gingivalis or Fusobacterium nucleatum modulates the inflammatory response, but fails to prevent experimental periodontitis.
Polak D; Wilensky A; Shapira L; Weiss EI; Houri-Haddad Y
J Clin Periodontol; 2010 Sep; 37(9):812-7. PubMed ID: 20670341
[TBL] [Abstract][Full Text] [Related]
13. The role of cytokines in a Porphyromonas gingivalis-induced murine abscess model.
Alayan J; Gemmell E; Ford P; Hamlet S; Bird PS; Ivanovski S; Farah CS
Oral Microbiol Immunol; 2007 Oct; 22(5):304-12. PubMed ID: 17803627
[TBL] [Abstract][Full Text] [Related]
14. Role for Porphyromonas gingivalis in the progression of atherosclerosis.
Wang Q; Zhou X; Huang D
Med Hypotheses; 2009 Jan; 72(1):71-3. PubMed ID: 18829178
[TBL] [Abstract][Full Text] [Related]
15. Porphyromonas gingivalis accelerates atherosclerosis in C57BL/6 mice fed a high-fat diet.
Fukasawa A; Kurita-Ochiai T; Hashizume T; Kobayashi R; Akimoto Y; Yamamoto M
Immunopharmacol Immunotoxicol; 2012 Jun; 34(3):470-6. PubMed ID: 22047042
[TBL] [Abstract][Full Text] [Related]
16. Transcutaneous immunization with a 40-kDa outer membrane protein of Porphyromonas gingivalis induces specific antibodies which inhibit coaggregation by P. gingivalis.
Maeba S; Otake S; Namikoshi J; Shibata Y; Hayakawa M; Abiko Y; Yamamoto M
Vaccine; 2005 Mar; 23(19):2513-21. PubMed ID: 15752838
[TBL] [Abstract][Full Text] [Related]
17. Nasal immunization with Porphyromonas gingivalis outer membrane protein decreases P. gingivalis-induced atherosclerosis and inflammation in spontaneously hyperlipidemic mice.
Koizumi Y; Kurita-Ochiai T; Oguchi S; Yamamoto M
Infect Immun; 2008 Jul; 76(7):2958-65. PubMed ID: 18426881
[TBL] [Abstract][Full Text] [Related]
18. Enhanced monocyte migration and pro-inflammatory cytokine production by Porphyromonas gingivalis infection.
Pollreisz A; Huang Y; Roth GA; Cheng B; Kebschull M; Papapanou PN; Schmidt AM; Lalla E
J Periodontal Res; 2010 Apr; 45(2):239-45. PubMed ID: 19778327
[TBL] [Abstract][Full Text] [Related]
19. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit.
Takahashi Y; Kumada H; Hamada N; Haishima Y; Ozono S; Isaka M; Yasuda Y; Tochikubo K; Umemoto T
Oral Microbiol Immunol; 2007 Dec; 22(6):374-80. PubMed ID: 17949339
[TBL] [Abstract][Full Text] [Related]
20. Protective immunity to Porphyromonas gingivalis infection in a murine model.
Bird PS; Gemmell E; Polak B; Paton RG; Sosroseno W; Seymour GJ
J Periodontol; 1995 May; 66(5):351-62. PubMed ID: 7623254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
